Koru Medical Systems, Inc. KRMD
We take great care to ensure that the data presented and summarized in this overview for KORU Medical Systems, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KRMD
View all-
First Light Asset Management, LLC Edina, MN4.68MShares$18.4 Million2.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.09MShares$8.18 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA997KShares$3.91 Million0.0% of portfolio
-
Meros Investment Management, LP Dallas, TX850KShares$3.33 Million1.56% of portfolio
-
Archon Capital Management LLC Seattle, WA700KShares$2.74 Million2.33% of portfolio
-
Acuitas Investments, LLC402KShares$1.58 Million1.4% of portfolio
-
State Street Corp Boston, MA394KShares$1.55 Million0.0% of portfolio
-
Rbf Capital, LLC San Francisco, CA357KShares$1.4 Million0.06% of portfolio
-
Albion Financial Group356KShares$1.4 Million0.09% of portfolio
-
Northern Trust Corp Chicago, IL324KShares$1.27 Million0.0% of portfolio
Latest Institutional Activity in KRMD
Top Purchases
Top Sells
About KRMD
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Insider Transactions at KRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 28
2025
|
Adam R Kalbermatten Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+50.0%
|
-
|
|
Jul 02
2025
|
Robert Cascella Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,189
+4.72%
|
$12,567
$3.58 P/Share
|
|
Jul 02
2025
|
Shahriar Matin Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,189
+4.56%
|
$12,567
$3.58 P/Share
|
|
Jul 02
2025
|
Edward Wholihan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,189
+9.98%
|
$12,567
$3.58 P/Share
|
|
Jul 02
2025
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,284
+2.88%
|
$18,852
$3.58 P/Share
|
|
Jul 02
2025
|
Donna French Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,189
+4.7%
|
$138,237
$33.58 P/Share
|
|
Jun 30
2025
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
4,189
+0.07%
|
-
|
|
May 20
2025
|
Joseph M. Manko Jr. Director |
SELL
Other acquisition or disposition
|
Indirect |
14,317
-0.24%
|
-
|
|
Apr 21
2025
|
Linda M Tharby President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,587
-2.25%
|
$47,174
$2.2 P/Share
|
|
Apr 02
2025
|
Shahriar Matin Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,870
+6.57%
|
$11,740
$2.56 P/Share
|
|
Apr 02
2025
|
Edward Wholihan Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,870
+14.88%
|
$11,740
$2.56 P/Share
|
|
Apr 02
2025
|
Robert Cascella Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,870
+6.8%
|
$11,740
$2.56 P/Share
|
|
Apr 02
2025
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,806
+4.11%
|
$17,612
$2.56 P/Share
|
|
Apr 02
2025
|
Donna French Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,870
+6.77%
|
$11,740
$2.56 P/Share
|
|
Mar 31
2025
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
5,870
+0.1%
|
-
|
|
Mar 19
2025
|
Linda M Tharby President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
29,813
-2.77%
|
$59,626
$2.83 P/Share
|
|
Mar 19
2025
|
Christopher Pazdan Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,849
-15.21%
|
$25,698
$2.83 P/Share
|
|
Mar 19
2025
|
Christopher Pazdan Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,331
+30.07%
|
-
|
|
Mar 17
2025
|
Linda M Tharby President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,848
-0.82%
|
$17,696
$2.89 P/Share
|
|
Mar 17
2025
|
Linda M Tharby President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,968
+1.45%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 426K shares |
|---|---|
| Other acquisition or disposition | 1.35M shares |
| Exercise of conversion of derivative security | 68.7K shares |
| Other acquisition or disposition | 2.03M shares |
|---|---|
| Payment of exercise price or tax liability | 80.9K shares |